Complement inhibition for prevention of antibody‐mediated rejection in immunologically high‐risk heart allograft recipients-Reference-Cited by-同舟云学术

Complement inhibition for prevention of antibody‐mediated rejection in immunologically high‐risk heart allograft recipients

Published:2021-02-11 Issue:7 Volume:21 Page:2479-2488
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Patel Jignesh K.¹^ORCID,Coutance Guillaume¹²³^ORCID,Loupy Alexandre³⁴^ORCID,Dilibero Deanna⁵,Hamilton Michele¹,Kittleson Michelle¹,Kransdorf Evan¹^ORCID,Azarbal Babak¹,Seguchi Osamu¹⁶,Zhang Xiaohai⁷^ORCID,Chang David¹,Geft Dael¹,Czer Lawrence¹^ORCID,Varnous Shaida²,Kobashigawa Jon A.¹^ORCID

Affiliation:

1. Department of Cardiology Cedars‐Sinai Medical Center Smidt Heart Institute Los Angeles California USA

2. Department of Cardiac and Thoracic Surgery Cardiology Institute, Pitié‐Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP‐HP), Sorbonne University Medical School Paris France

3. Paris Translational Research Centre for Organ Transplantation Université de Paris, INSERM Paris France

4. Kidney Transplant Department Necker HospitalAssistance Publique ‐ Hôpitaux de Paris Paris France

5. Department of Pharmacy Cedars‐Sinai Medical Center Los Angeles California USA

6. Department of Transplant Medicine National Cerebral and Cardiovascular Center Osaka Japan

7. HLA Laboratory, Comprehensive Transplant Center Cedars‐Sinai Medical Center Los Angeles California USA

Funder

Alexion Pharmaceuticals

Fédération Française de Cardiologie

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.16420

Reference32 articles.

1. The management of antibodies in heart transplantation: An ISHLT consensus document

2. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

3. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance

4. Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy

5. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing immunosuppression in liver transplantation: A narrative review;Hepatobiliary & Pancreatic Diseases International;2024-10

2. Cardiovascular disease and cancer: shared risk factors and mechanisms;Nature Reviews Cardiology;2024-04-10

3. Canonical and non-canonical roles of complement in atherosclerosis;Nature Reviews Cardiology;2024-04-10

4. IgM marks persistent IgG anti-human leukocyte antigen antibodies in highly sensitized heart transplant patients;The Journal of Heart and Lung Transplantation;2024-02

5. Modern advances in heart transplantation;Progress in Cardiovascular Diseases;2024-01